ACSF3 and metabolic dysfunction-associated steatotic liver disease: With its strong affinity for acyl-CoA synthetase family member 3 (ACSF3), PCA activates sirtuin 3 (SIRT3) by inhibiting ACSF3-mediated fatty acid metabolism, thereby preventing MASLD development [152].